CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Guanfacinedrug
Likely dose
Guanfacine 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01467999
NCT01467999Phase 1Completed
CompareCT.gov

Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence

New York State Psychiatric Institute·interventional·Posted Nov 9, 2011·Updated Feb 5, 2019

In Brief

A Phase 1 clinical trial evaluating Guanfacine for Cannabis Dependence. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether guanfacine represents a tolerable, potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving as compared to baseline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 9, 2011
Enrollment StartFeb 1, 2012
Primary CompletionApr 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 14.6 years ago

Interventions

Guanfacinedrug

Guanfacine, 4mg given once daily